Zacks Investment Research upgraded shares of GENFIT S A/ADR (NASDAQ:GNFT) from a hold rating to a buy rating in a report published on Wednesday morning, Zacks.com reports. They currently have $18.00 target price on the stock.
According to Zacks, “Genfit SA is a biopharmaceutical company. It focuses on the discovery and development of therapeutic and diagnostic solutions in metabolic and liver related diseases. The company’s lead products include Elafibranor, Nitazoxanide and TGFTX1 which are in clinical stage. Genfit SA is based in Loos, France. “
GNFT has been the topic of a number of other reports. Svb Leerink initiated coverage on GENFIT S A/ADR in a research note on Wednesday, April 24th. They issued an outperform rating and a $58.00 price target on the stock. Stifel Nicolaus initiated coverage on GENFIT S A/ADR in a research note on Tuesday, June 25th. They issued a hold rating on the stock. Roth Capital restated a buy rating on shares of GENFIT S A/ADR in a research note on Tuesday, April 23rd. HC Wainwright decreased their price target on GENFIT S A/ADR to $72.00 and set a buy rating on the stock in a research note on Monday, April 22nd. Finally, Barclays began coverage on GENFIT S A/ADR in a research note on Monday, April 22nd. They issued an overweight rating and a $55.00 price target on the stock. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has an average rating of Buy and an average price target of $45.69.
A number of hedge funds have recently modified their holdings of the stock. Victory Capital Management Inc. acquired a new position in GENFIT S A/ADR during the first quarter worth $2,358,000. TT International acquired a new position in GENFIT S A/ADR during the first quarter worth $1,200,000. Bank of America Corp DE acquired a new position in GENFIT S A/ADR during the second quarter worth $889,000. Balyasny Asset Management LLC acquired a new position in GENFIT S A/ADR during the second quarter worth $699,000. Finally, One68 Global Capital LLC acquired a new position in GENFIT S A/ADR during the first quarter worth $270,000. 14.69% of the stock is owned by hedge funds and other institutional investors.
GENFIT S A/ADR Company Profile
Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, and autoimmune or fibrotic diseases affecting primarily the liver and gastro-enterology. The company's lead products include Elafibranor, which is in pivotal Phase 3 clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as in Phase 2 study in patients with primary biliary cholangitis; and Nitazoxanide that is in Phase 2 proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis.
Read More: The primary rules of Elliott Wave theory
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GENFIT S A/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENFIT S A/ADR and related companies with MarketBeat.com's FREE daily email newsletter.